

Paris &amp; New York, April 25, 2017

## Quantum Genomics appoints Bruno Besse as Chief Medical Officer

**Quantum Genomics (Alternext - FR0011648971 - ALQGC)**, a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces the appointment of Dr Bruno Besse as the Company's Chief Medical Officer.

Dr Besse will be in charge of all patient-related clinical development, interactions with regulators, and pharmacovigilance activities. He will also supervise patient stratification and the positioning of Quantum Genomics' drug candidates.

A cardiologist at Georges Pompidou Hospital (Paris, France), Bruno Besse has held numerous positions in the Medical Affairs departments of companies in the pharmaceutical industry. In 2011, he was appointed Global Medical Officer in the Cardiology Division of the U.S. company Bristol-Myers Squibb. Prior to that, he also served as Chief Medical Officer at Crossject, Aventis (now Sanofi) and Boehringer-Mannheim (now Roche).

Awarded his MD by University Paris-Sud (Paris XI), he also holds a post-graduate degree in Biostatistics and is a graduate of INSEAD.

### Lionel Ségard, Chairman & CEO of Quantum Genomics, says:

*"We are delighted to welcome Dr Bruno Besse to our management team at Quantum Genomics. He brings more than 20 years' experience in the Medical Affairs departments of major players in the pharmaceutical industry, and a wealth of experience in cardiology."*

## CONTACTS

### Quantum Genomics

Lionel Ségard  
Chairman & Chief Executive Officer  
+33 1 85 34 77 77

### Quantum Genomics

Marc Karako  
CFO – Investor Relations  
+33 1 85 34 77 75  
[marc.karako@quantum-genomics.com](mailto:marc.karako@quantum-genomics.com)

### ACTUS finance & communication (Europe)

Jean-Michel Marmillon  
Press Relations  
+33 1 53 67 36 73  
[jmarmillon@actus.fr](mailto:jmarmillon@actus.fr)

### Edison Advisors (U.S.)

Tirth Patel  
Investor Relations  
+1 (646) 653-7035  
[tpatel@edisongroup.com](mailto:tpatel@edisongroup.com)

## ABOUT QUANTUM GENOMICS

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially hypertension and heart failure.

The Company is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.

Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).

The Company has offices in Paris, France, and New York, NY, USA. For more information, please visit [www.quantum-genomics.com](http://www.quantum-genomics.com).

 @ALQGC\_EN

 Quantum Genomics